Recently, Professor Lu Changlin, a young cardiologist in China and a cardiologist from the Department of Cardiology at Beijing Chaoyang Hospital affiliated with Capital Medical University, edited the first book in China titled "Today's Coronary Heart Disease", which was published and distributed by the People's Health Publishing House. This book lasted for more than 5 years, and Professor Lu Changlin organized over a hundred domestic experts and scholars who have long been committed to the clinical diagnosis and treatment of cardiovascular diseases to participate in the editing. After numerous drafts, repeated discussions, and finally publication, it met with a large number of readers. Editor in Chief of "Today's Coronary Heart Disease": Lu Changlin; Deputy Editors in Chief: Liu Deping, Yu Mengyue, Qian Haiyan, Ren Jingyi. Vascular disease is an important disease that threatens human health. Due to the transformation of people's lifestyles in recent years, it has brought many multiple risk factors that seriously affect the onset, occurrence, and development of cardiovascular disease. For example, the continuation of unhealthy lifestyles such as smoking, high calorie intake, sitting still (lack of exercise) and staying up late, and the incidence rate of coronary heart disease caused by metabolic abnormalities such as diabetes, dyslipidemia, hypertension and hyperuricemia is increasing year by year. Since the 1970s, with the continuous progress of new technologies and concepts in the diagnosis and treatment of coronary heart disease, more experts and scholars in the field of heart disease have proposed a multi-dimensional research orientation for coronary heart disease, thereby reducing the important connotation of human cardiovascular disease mortality, and bringing about rapid changes in the diagnosis and treatment of coronary heart disease. Among them, drug therapy, interventional therapy, surgical bypass surgery, and composite or hybrid therapy with a combination of internal and external medicine have saved the lives of many patients with coronary heart disease. Opening 'Today's Coronary Heart Disease', the text is simple and plain, the content is easy to understand, and the charts are clear and novel; These are all cited from authoritative journals or books, or from the practical summaries and updates of numerous editors. Both newly enrolled students and senior scholars in the cardiovascular field can benefit greatly from "Today's Coronary Heart Disease". Upon closer reading, it can be seen that "Today's Coronary Heart Disease" can become an important reference book and reference book for many cardiologists. The biggest feature of this book is its editing, arrangement, and focus. This book highlights the knowledge content of today's (current) coronary heart disease field, and highlights the "practicality" and "forward-looking" characteristics of clinical diagnosis and treatment of coronary heart disease. In terms of length, this book greatly reduces the simple and separate discussions on the pathogenesis, but integrates and intersperses this part of content into comprehensive and accurate diagnosis and treatment practice of coronary heart disease. From the perspective of the proportion of the entire text, out of a total of thirteen articles on drug therapy, there are four new and exciting content: five, six, seven, and eight. In addition, two articles on interventional therapy and other treatments occupy nearly half of the space, which is sufficient to reflect the focus and unique thinking of this book. It explains the "four new" concepts that the editor has always adhered to in writing, namely, responding to new situations, based on new models, promoting new technologies, and keeping up with new hotspots, I hope to bring readers a new visual experience. This book presents the "progressiveness" closely following the hot research topics at home and abroad, covering the latest progress in the field of coronary heart disease research. In the section of drug therapy, not only classic commonly used drugs such as aspirin and clopidogrel are discussed, but also drugs such as hirudin, polydecanol, and cholesterol ester transfer protein, which are only found in various guidelines but are less commonly used in China. Not only that, readers can also refer to